Medicare will continue to restrict coverage of a new class of Alzheimer’s drugs, even when fully approved by the Food and Drug Administration (FDA)

Title: Medicare won’t change coverage policy for pricey Alzheimer’s drugs

Article Snip: "Currently, Medicare coverage is even stricter, as the agency will only pay for the drugs if a patient receives them through a clinical trial. The treatments in question are monoclonal antibody infusions that target brain plaque known as amyloid that’s a signature characteristic of Alzheimer’s disease. The drugs are intended for early stage Alzheimer’s patients and are meant to slow the progression of memory loss, but are not a cure. They are costly, and there are only two: Eisai’s Leqembi and Biogen’s Aduhelm. Both were granted accelerated approval by FDA..."

Reference: www.yahoo.com
Centers for Medicare and Medicaid Services (CMS)

---

---